Japanese Pharma Companies Speed Up Mergers And Acquisitions In Growing Biopharmaceutical Arena
This article was originally published in PharmAsia News
Major Japanese pharmaceutical companies have been in an uphill battle to develop new drugs, and as the biopharmaceutical industry captures attention, they are increasingly turning to mergers and acquisitions overseas with leading international biopharmaceutical companies. Eisai bought an American biopharma venture for ¥430 billion. Last year, Takeda set up an antibody research facility in San Francisco, where many of America's biopharma companies are concentrated. On Feb. 4, Takeda announced a buyout of Amgen's wholly-owned business unit in Japan. Through the purchase, Takeda obtained licensing rights for the sole development and marketing of 13 new drugs in Japan, including cancer drug AMG706 (motesanib) and other antibody drugs. It is expected that the buyout will speed up Takeda's presence in this growing area. (Click for more-Japanese language
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.